France's Boiron Reaping The Benefits Of Product Investments
Boiron's decision to diversify its portfolio away from non-proprietary homeopathic medicines is paying off, with sales for the opening nine months of 2022 up by a quarter, driven by new product launches in categories such as cosmetics and dietary supplements.
You may also be interested in...
Boiron Moves Into Personalized Beauty As Sales Continue To Slide
France's Boiron has acquired cosmetics player ABBI, which uses artificial intelligence to offer consumers personalized beauty products. The move comes as Boiron reported 2021 sales down double-digits as homeopathy sales in its home market continue to decline.
France's Boiron Strikes Deal With Bionorica As Q3 Sales Edge Up
Boiron has gained the rights to distribute Bionorica's Canephron herbal medicine in France as it continues to diversify its portfolio away from homeopathy.
France's Boiron Diversifies Into Probiotics To Arrest Sales Decline
Homeopathy specialist Boiron its diversifying its offering into the increasingly popular probiotics segment with launches underway in France, Italy and Spain, as well as Eastern Europe.